98%
921
2 minutes
20
The Korean Gynecologic Oncology Group (KGOG) was established in 2002 and is the only organization in Korea conducting multi-center clinical trials for gynecologic cancers. Since its re-establishment as a non-profit organization in 2021, KGOG has grown significantly, now including 207 gynecologic oncology specialists from 76 hospitals. This growth is a testament to the dedication and hard work of all those involved in the organization. KGOG is committed to maximizing the activation of multi-center clinical research through policies that support patients with rare diseases and gynecologic cancer research, focusing on strengthening institutional capacity, equalizing participation opportunities, and enhancing information sharing. A significant milestone for KGOG was becoming a member of the US Gynecologic Oncology Group (GOG) in 2005, allowing participation in GOG clinical trials. KGOG later joined the Gynecologic Cancer InterGroup (GCIG) and strengthened its capabilities by hosting the first Endometrial Cancer Consensus Conference-Clinical Research (ECCC-CR) in 2023. KGOG holds biannual meetings and symposia, as well as 224 operating committee meetings annually to review the discussions of the Tumor Site Committee. KGOG has conducted 156 investigator-initiated trial (IIT) or sponsor-initiated trial (SIT) studies as KGOG-led or participated in research. Currently, 18 studies are registered, and 10 are in preparation. To date, 68 papers have been published. KGOG conducts six national projects and collaborates with external organizations such as the NRG Oncology Foundation, Gynecologic Oncology Group Partners (GOG-P), GCIG, East Asian Gynecologic Oncology Trial group (EAGOT), and the Japanese Gynecologic Oncology Group (JGOG). Through collaboration with renowned international research institutions, KGOG has significantly expanded the scope of its research, achieving noteworthy clinical outcomes. This report not only introduces the history and recent status of KGOG but also presents the exciting future direction of the organization, filled with potential breakthroughs and advancements in gynecologic oncology research.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11475356 | PMC |
http://dx.doi.org/10.3390/cancers16193422 | DOI Listing |
Menopause
September 2025
Department of Gynecologic Oncology, Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY.
Objective: Endometrial cancer (EC) and epithelial ovarian cancer (EOC) affect women of all ages, and the incidence of endometrial cancer in premenopausal women is rising. Menopause can be detrimental to longevity and quality of life, but evidence suggests estrogen therapy (ET) is safe in these patients. The purpose of this study was to evaluate the practice patterns of gynecologists and gynecologic oncologists (GYO) in the United States in regards to prescription of ET to gynecologic cancer patients.
View Article and Find Full Text PDFAm J Reprod Immunol
September 2025
Department of Obstetrics and Gynecology, Gazi University Faculty of Medicine, Ankara, Turkey.
Problem: Endometriosis is a chronic inflammatory disease that leads to pelvic pain and infertility. Recent studies have indicated that immunological, endocrine, biochemical, and genetic irregularities, along with suboptimal quality of oocytes, embryos, and the endometrial environment, significantly impact infertility associated with endometriosis. Ectopic endometrial cells in endometriosis have the capacity to avoid apoptosis.
View Article and Find Full Text PDFObstet Gynecol
July 2025
Ana I. Tergas is from the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Health, Rutgers New Jersey Medical School, Newark, New Jersey. Mark H. Einstein is from the Department of Obstetrics, Gynecology, and Women's Health, Albert Einstein College of Medicine
Clin Transl Oncol
September 2025
Ophthalmology Unit, Cannizzaro Hospital, 95126, Catania, Italy.
Antibody-drug conjugates (ADCs) represent a promising therapeutic approach in gynecologic cancers, particularly ovarian and cervical malignancies. Agents such as mirvetuximab soravtansine, and tisotumab vedotin, targeting folate receptor alpha and tissue factor, respectively, reported clinical efficacy in patients with limited options. However, their use is associated with ocular toxicities, including keratopathy, blurred vision, and dry eye, which may impact adherence and quality of life.
View Article and Find Full Text PDFJ Robot Surg
September 2025
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, UT Health San Antonio, 7703 Floyd Curl Drive, 7836, San Antonio, TX, 78229-3900, USA.
To evaluate intraoperative ventilatory mechanics during robotic-assisted hysterectomy in obese women with endometrial cancer and introduce the concept of a physiologic "ceiling effect" in respiratory strain. We conducted a retrospective cohort study of 89 women with biopsy-confirmed endometrial cancer who underwent robotic-assisted total hysterectomy between 2011 and 2015. Intraoperative ventilatory parameters, including plateau airway pressure and static lung compliance, were recorded at five-minute intervals.
View Article and Find Full Text PDF